2hon MSN
Forget Ozempic: This high‑flying device maker can thrive no matter which weight loss drug wins
Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.
We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Dexcom, Inc. (NASDAQ:DXCM) stands against the other ...
People have been riding the GLP-1 wave to achieve quick and significant weight loss. But given the drug’s effect on controlling type 2 diabetes, it’s no surprise that DexCom CEO Jake Leach wants to ...
StockStory.org on MSN
3 reasons investors love DexCom (DXCM)
Over the last six months, DexCom’s shares have sunk to $62.07, producing a disappointing 6.4% loss - a stark contrast to the ...
Abbott Laboratories (NYSE: ABT) and Dexcom (NASDAQ: DXCM) are two leading medical device companies that compete against one ...
Add Yahoo as a preferred source to see more of our stories on Google. Dexcom is poised to share new data on the benefits of its continuous glucose monitoring technology (CGM), which the company says ...
One common problem in this market is that the conventional cold storage method used to store and transport organs often leads ...
Investors have been bearish on DexCom's numbers all this past year. The opportunity in diabetes care, however, remains significant in the long run. The launch of glucose monitor Stelo should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results